公司资料
Smith and Nephew 股价、新闻与催化剂
- 股票代码:
- SNN
- 交易所:
- NYSE
- 行业:
- MedTech
- 所在地:
- United Kingdom and listed in the U
股票表现
29.04 USD (-0.92%)
收盘价
最后更新: 2026年8月20日
12.5B USD
市值
股价为何变动
As of Aug 20, 2026, SNN closed down 0.92% at $29.04. No new same-company headline was identified in the current news window.
公司概览
业务概览
Smith & Nephew is a global medical technology company focused on orthopedics, sports medicine, and advanced wound management. Its business is driven by procedure-linked demand and product innovation across surgical and restorative care.
所在地与行业分类
Headquartered in the United Kingdom and listed in the U.S. as an ADR, Smith & Nephew has a broad international footprint. It sits in medtech rather than biotech.
商业模式特征
The company earns revenue through implants, surgical systems, wound care, and related products used in hospitals and clinics. Investors watch procedure volumes, product launches, and margin trends across its core franchises.
生物医药行业定位
Smith & Nephew is outside biotech but important within healthcare technology because it benefits from surgical and wound-care demand. It tends to move on clinical adoption and hospital utilization rather than drug events.
未来催化剂
- Smith & Nephew’s watchpoints are robotics adoption, sports-medicine execution, and continued recovery in orthopedics. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。